大博医疗实控人方拟减持 2023套现2.6亿2022定增募5亿

Core Viewpoint - The major shareholder of Dabo Medical, Dabo International Investment Co., Ltd., plans to reduce its stake in the company, which may impact the stock's performance and investor sentiment [1][2][3]. Shareholder Reduction Plan - Dabo International holds 82,926,901 shares, representing 20.03% of the total share capital, and plans to reduce its holdings by up to 8,280,390 shares, or 2.00% of the total share capital, within three months from the announcement date [1]. - The reduction will occur through centralized bidding or block trading methods [1]. Shareholding Changes - From October 17, 2022, to September 1, 2023, Dabo International's shareholding decreased by 8,280,000 shares (2.00%), while Zhao Shaomei's shareholding decreased by 1,600,000 shares (0.39%), totaling a combined reduction of 9,880,000 shares (2.39%) [2]. Completion of Reduction Plan - As of December 23, 2023, Dabo International completed its reduction plan, having sold a total of 9,137,389 shares, which is 2.21% of the total share capital, for a total amount of 264 million yuan [3]. - The shares were sold at an average price of 38.80 yuan during the last trading period [3]. Company Control and Structure - The actual controllers of Dabo Medical are Lin Zhixiong and Lin Zhijun, who are siblings, while Zhao Shaomei is the mother-in-law of Lin Zhijun [3]. - Dabo International serves as the holding platform for the actual controllers, with its main asset being a 25.57% stake in Dabo Medical [3]. Fundraising Activities - Dabo Medical raised 496.32 million yuan through a non-public offering of 12 million shares at a price of 41.36 yuan per share, with net proceeds amounting to 487.22 million yuan after deducting related expenses [4].